Prenetics Global Limited PRE
Nov 6, 2026, 11:03 AM EST
- YTD
- +1.59%
- 1 year
- +29.55%
- Market cap
- 312.23M
- Revenue (ttm)
- 22.66M
- Profit margin
- -219.78%
- EPS (ttm)
- -3.10
- Shares out
- 10.64M
- Forward P/E
- -10.10
- YTD return
- +1.59%
- 1-year return
- +29.55%
- Volume
- 44.80K
- Avg volume
- 218.33K
- Open
- 15.51
- Previous close
- 16.12
- Day's range
- 15.21 – 16.33
- 52-week range
- 11.37 – 27.24
- Beta
- -0.21
- Price target
- 9.00 (-43.8%)
- Earnings date
- Oct 7, 2024
5D -2.37 (-12.84%)
Key statistics
- Enterprise value
- -3.77M
- PEG ratio
- 0.00
- Price / sales
- 3.05
- Price / book
- 0.33
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 4.30%
- Free cash flow
- 0
- Total cash
- 63.89M
- Total debt
- 2.36M
- Return on equity
- -21.67%
- Short % of float
- 0.37%
- 50-day average
- 4.80
- 200-day average
- 5.03
Analyst view
- Strong buy0
- Buy1
- Hold0
- Sell0
- Strong sell0
Next earnings
Oct 7, 2024
Expected Oct 7, 2024. Consensus EPS estimate 0.00.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 27, 2024 | Sep 1, 2024 | 0.00 | -0.84 | — | — |
| Oct 7, 2024 | Jun 1, 2024 | 0.00 | -0.88 | — | — |
| Oct 7, 2024 | Jun 1, 2024 | 0.00 | — | — | — |
| Jun 18, 2024 | Mar 1, 2024 | 0.00 | -0.38 | — | — |
| Jun 18, 2024 | Mar 1, 2024 | 0.00 | — | — | — |
| Apr 1, 2024 | Dec 1, 2023 | 0.00 | -0.52 | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 4, 2024 | Cantor Fitzgerald | reit | Overweight | Overweight |
| Apr 4, 2024 | Cantor Fitzgerald | main | Overweight | Overweight |
About Prenetics Global Limited
Prenetics Global Limited, a health sciences company, focuses on advancing consumer and clinical health. The company's consumer initiatives is led by IM8, a new health and wellness brand. Its prevention arm, CircleDNA, uses next-generation sequencing (NGS) technology to offer comprehensive consumer DNA test. It also develops and commercializes multi-cancer early detection technologies. In addition, the company offers a range of genomic profiling panels tailored for requirements and clinician needs, including ACTOnco, ACT HRD, ACTFusion, and ACTDrug tests. Further, the company offers ACTLiquid Pro, a sequencing based liquid biopsy assay for pan-solid tumors; ACTMonitor, which provides real time monitoring of drug resistance, treatment response, and cancer recurrence; and ACT Risk, which manages the cancer risk. Additionally, it is involved in the sports distribution activities providing sports nutrition products to fitness facilities. The company operates in Taiwan, Hong Kong, the United Kingdom, and internationally. The company was founded in 2014 and is based in Quarry Bay, Hong Kong and has a presence in the United States.
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Country
- Hong Kong
- Website
- prenetics.com
News
Prenetics Global Collaborates With Authentic Brands Group To Build Care Bears By IM8 
Care Bears And Prenetics' IM8 Announce Global Partnership 
Prenetics' IM8 and Authentic Brands Group Announce 10-Year Exclusive Global Partnership to Create Care Bears by IM8; Authentic to Become Strategic Shareholder in Prenetics 
Prenetics Global Appoints Brian J. Rosin CFO, Effective Dec. 31, Succeeding Stephen Lo 
Prenetics' IM8 Names Brian J. Rosin as Successor Chief Financial Officer 
Maxim Group Initiates Coverage On Prenetics Global with Buy Rating, Announces Price Target of $41 - Lucid Capital Markets Initiates Coverage On Prenetics Global with Buy Rating, Announces Price Target of $54
Prenetics Global Q2 2026 Earnings Call: Complete Transcript 
Craig-Hallum Initiates Coverage On Prenetics Global with Buy Rating, Announces Price Target of $40 - B. Riley Securities Initiates Coverage On Prenetics Global with Buy Rating, Announces Price Target of $37
Your note
Sign in to keep a note on PRE — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Prudential PLC | 4.03% | 427,963 | 2.42M | Sep 29, 2024 |
| Aspex Management (HK) Ltd | 3.26% | 346,150 | 1.96M | Sep 29, 2024 |
| Nomura Holdings Inc. | 3.04% | 322,952 | 1.83M | Sep 29, 2024 |
| UBS Group AG | 0.12% | 12,477 | 70.55K | Sep 29, 2024 |
| Morgan Stanley | 0.02% | 2,374 | 13.42K | Sep 29, 2024 |
| Aspire Private Capital, LLC | 0.00% | 114 | 644 | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity NASDAQ Composite Index Fund | 0.06% | 6,514 | 36.83K | Oct 30, 2024 |